cdr
Search

Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top
  1. Home
  2. About
  3. Editorial Board

Editorial Board

Editor-in-Chief

Editorial Board Members

  • Aamir Ahmad
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
    Research Interests: non-coding RNAs expression, signaling in cancer metastasis, circulating and tissue biomarkers.
    Contributions:
  • Suresh V. Ambudkar
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
    Research Interests: ATP-binding cassette (ABC) drug transporters, drug resistance, membrane biochemistry, chemoresistance, transport proteins.
  • Yehuda G. Assaraf
    Fred Wyszkowski Cancer Research Laboratory, Technion - Israel Institute of Technology, Haifa, Israel.
    Research Interests: molecular mechanisms of anticancer drug resistance.
  • Benjamin Bonavida
    Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
    Research Interests: apoptosis, immunotherapy resistance, cancer drug resistance.
    Contributions:
  • Stergios Boussios
    Oncology Department，Medway NHS Foundation Trust, Kent, UK.
    Research Interests: cancer treatment, cancer in pregnancy, cancer diagnostics, cancer biology, cancer biomarkers, gynaecological cancers, urological cancers, colorectal cancer, autoimmunity.
  • Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, Christian Albrechts University Kiel, Hospitalstr. 4, Kiel, Germany.
    Research Interests: cancer biology, pharmacokinetics, genotyping, mutation, DNA, genetics, enzymes, drug safety, pharmaceutical development, intensive care medicine.
    Contributions:
  • Claudio Cerchione
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
    Research Interests: myelodysplastic syndromes, hematological malignancies, lymphoma, multiple myeloma, hematologic diseases, clinical hematology, blood disorders, acute myeloid leukemia, chemotherapy, leukemia, acute lymphoblastic leukemia.
  • Zhe-Sheng (Jason) Chen
    Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA.
    Research Interests: ABC transporters, multidrug resistance, cancer pharmacology.
  • Jacqueline Cloos
    Department of Hematology, Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
    Research Interests: proteasome inhibitors, minimal residual disease, clonal evolution, splicing, cellular drug addiction, hematology, drug combination studies.
  • Paul Dent
    Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.
    Research Interests: cancer therapeutics, rational combination of drugs, molecular mechanisms, drug combinations synergize, breast, brain, liver/pancreatic cancers.
    Contributions:
  • Thomas Efferth
    Department of Pharmaceutical Biology, Institute of Biochemistry and Pharmacy, Johannes Gutenberg University, Staudinger Weg 5, Mainz, Germany.
    Research Interests: natural product chemistry, medicinal and pharmaceutical chemistry, virtual drug screening, transcriptomics, network pharmacology, biochemistry, drug development, apoptosis, cancer biology.
    Contributions:
  • Wafik S. El-Deiry
    Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
    Research Interests: p53 tumor suppression, autophagy, cell death signaling pathways, DNA damage, TRAIL pathway, hypoxia, drug resistance, novel therapeutics, translational oncology.
  • Marco Falasca
    Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.
    Research Interests: pancreatic cancer, exosomes, lipid metabolism, membrane transporters, signal transduction, cancer invasion and metastasis, phosphoinositide signalling, cannabinoids.
  • Carlos G. Ferreira
    Oncoclinica Group, Oncoclinical Institute, Rio de Janeiro, Brazil.
    Research Interests: immune microenvironment, non-small-cell lung cancer.
  • Liwu Fu
    Department of Experimental Research (Cancer Institute), Sun Yat-sen University, Guangzhou, China.
    Research Interests: ABC transporter, cancer therapy, chemotherapy resistance, multidrug resistance, immune checkpoint blockade, leukemia.
  • Jean-Pierre Gillet
    Laboratory of Molecular Cancer Biology, Department of Biomedical Sciences, Faculty of Medicine, University of Namur, Namur, Belgium.
    Research Interests: ATP-binding cassette transporters, cancer multidrug resistance mechanisms, pharmacogenomics, cancer biology, transcriptomics.
  • Elisa Giovannetti
    Lab Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisana per la Scienza, Pisa, Italy.
    Research Interests: molecular pharmacology, chemoresistance, pancreatic cancer, thoracic cancers.
    Contributions:
  • William Gmeiner
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
    Research Interests: colorectal cancer, fluoropyrimidine, thymidylate synthase, DNA topoisomerase, aberrant signaling pathways in tumor cells.
    Contributions:
  • Ivana Grivicich
    Cancer Biology Laboratory, Lutheran University of Brazil, Canoas, Brazil.
    Research Interests: breast cancer, colon cancer, cell culture, apoptosis.
    Contributions:
  • Sanjay Gupta
    Department of Urologic Oncology, Case Western Reserve University, Cleveland, Ohio, USA.
    Research Interests: cancer chemoprevention, cancer therapeutics, drug resistance, drug repurposing, translational oncology, cancer biology, signal transduction, apoptosis, antioxidant activity, artificial intelligence, cancer biomarkers, diet nutrition and cancer, drug delivery, toxicology, epigenetics, inflammation, cancer stem cells.
    Contributions:
  • Georg Hempel
    Clinical Pharmacy Group, Department of Pharmaceutical and Medical Chemistry, University of Münster, Münster, Germany.
    Research Interests: capillary electrophoresis, chromatography, pharmacokinetics, drug safety, oncology.
  • Dominique Heymann
    Institut de Cancérologie de l'Ouest, Université de Nantes, Saint-Herblain, France.
    Research Interests: circulating tumour cells, pathogenesis of bone sarcoma, osteoclast differentiation, metastatic process.
    Contributions:
  • Marja Jäättelä
    Cell Death and Metabolism Unit, Center for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Copenhagen, Denmark.
    Research Interests: autophagy, cancer progression, lysosomal, DNA, pH regulation.
  • Gerrit Jansen
    Department of Rheumatology, Amsterdam Rheumatology and immunology Center (ARC), Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
    Research Interests: rheumatology, cancer biology and immunology, imaging and biomarkers, inflammatory diseases, antifolates, proteasome inhibitors, (multi) drug resistance.
    Contributions:
  • Markus Joerger
    Division of Medical Oncology, University of Basel, Basel, Switzerland.
    Research Interests: thoracic malignancies, clinical pharmacology, pharmacogenetics, pharmacokinetics, immunotherapy.
  • Michael Kahn
    Department of Molecular Medicine, City of Hope's comprehensive cancer center, Duarte, CA, USA.
    Research Interests: chemical genomics, Wnt signaling.
    Contributions:
  • Ganna Kalayda
    Institute of Pharmacy, University of Bonn, Bonn, Germany.
    Research Interests: fluorescence microscopy, cell culture, live cell imaging, fluorescence imaging, flow cytometry, western blot analysis, cancer biology, immunofluorescence staining, intracellular trafficking, synthesis.
  • Hang Fai Kwok
    Faculty of Health Sciences, University of Macau, Macau, China.
    Research Interests: novel therapeutic antibodies development, venom-based peptide & natural biomolecule prototype drugs development, cancer biomarkers & immunotherapy markers discovery for prognostic and therapeutic validation
  • Lucia R. Languino
    Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
    Research Interests: signaling pathways, cross-talk between cell adhesion molecules, extracellular matrix proteins and growth factor receptors in vitro and in vivo systems, prostate cancer cells, signals directing distant localization, cellular and molecular characterization.
    Contributions:
  • Thomas Litman
    Faculty of Health and Medical Sciences, Department of Immunology & Microbiology, University of Copenhagen, Copenhagen, Denmark.
    Research Interests: bioinformatics, multi-omics, transcriptomics, proteomics, pharmacogenomics, metabolomics, microbiome analysis, machine learning, translational research, biomarker discovery, oncogenomics, multidrug resistance: MDR, P-glycoprotein, ABCG2, ATPase activity, transport kinetics.
  • Jose J. G. Marin
    Laboratory of Experimental Hepatology and Drug Targeting, National Institute for Study of Liver and Gastrointestinal Diseases, University of Salamanca, Salamanca, Spain.
    Research Interests: hepatology and drug targeting, liver and gastrointestinal diseases.
    Contributions:
  • Giovanni Martinelli
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
    Research Interests: leukemia, myelodysplastic syndromes, multiple myeloma, hematologic diseases, lymphoma, blood disorders, stem cell transplantation, chemotherapy, clinical hematology, hematology.
  • Cornelis J. M. Melief
    Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands.
    Research Interests: HLA (human leukocyte antigen), MHC, histocompatibility, immunotherapy, cancer research, clinical immunology, cancer vaccines.
  • Martin Michaelis
    School of Biosciences, University of Kent, Canterbury, UK.
    Research Interests: virology, emerging infectious diseases, apoptosis, virus, PCR, cancer cell line.
    Contributions:
  • Hans Minderman
    Department of Flow and Image Cytometry, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
    Research Interests: leukemia, lymphoma, imaging flow cytometry, multidrug resistance mechanisms, immunologically-based diseases, DNA in solid tumors.
  • Enrico Mini
    Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
    Research Interests: leukemia, antimetabolites and metal-based drug resistance, gastrointestinal cancers, cancer pharmacogenomics, pharmacogenetics.
    Contributions:
  • Priyabrata Mukherjee
    Department of Pathology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
    Research Interests: programming tumor microenvironment by nanoparticles, anti-angiogenic property of inorganic nanoparticles, metabolic enzyme and angiogenesis, identification of new molecular targets using nanotechnology, nanoendocytosis, understanding cellular processes using engineered nanoparticles, metabolic enzymes in cancer.
  • Patrycja Nowak-Sliwinska
    Molecular Pharmacology, School of Pharmaceutical Sciences (EPGL), University of Geneva, Geneva, Switzerland.
    Research Interests: multi drug combinations, drug-drug interactions, acquired drug resistance, cancer organoids, cancer treatment, tumor angiogenesis, targeted therapies.
  • Paola Perego
    Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
    Research Interests: molecular biology, p53, DNA damage, apoptosis, cytotoxicity, pharmacology, cancer cell line.
    Contributions:
  • Roger M. Phillips
    School of Pharmacy, University of Huddersfield, Huddersfield, UK.
    Research Interests: tumour hypoxia, cancer metabolism, hypoxia activated prodrugs, drug discovery (including phenotypic drug evaluation), drug delivery to the tumour microenvironment.
  • Raphael E. Pollock
    Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
    Research Interests: sarcoma, neoplasms, neurilemmoma, gastrointestinal stromal tumors, breast neoplasms, leiomyosarcoma, neoplasm metastasis, ewing, liposarcoma, myxoid, liposarcoma.
  • Chiara Riganti
    Department of Oncology, University of Torino Torino, Italy.
    Research Interests: chemo-immunoresistant tumor models, lung cancer, prostate cancer, breast cancer, malignant pleural mesothelioma, glioblastoma multiforme, multiple myeloma.
    Contributions:
  • Jose Antonio Rodriguez
    Department of Genetics, Physical Anthropology and Animal Physiology (School of Medicine) of the University of the Basque Country (UPV/EHU), Basque Country, Spain.
    Research Interests: molecular mechanisms of malignant transformation, protein ubiquitination, nucleocytoplasmic transport.
    Contributions:
  • José Rueff
    Nova Medical School (NMS), Universidade Nova de Lisboa/Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal.
    Research Interests: genetics, bacterial cell culture, immunohistochemistry, biochemistry, genomics, PCR, gene expression, cell culture, DNA, cancer biology.
    Contributions:
  • Afshin Samali
    Apoptosis Research Centre, National University of Ireland, Galway, Ireland.
    Research Interests: apoptosis, endoplasmic reticulum, UPR signaling in cancer, IRE1, PERK, drug discovery, biomarker discovery.
  • Gautam Sethi
    Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
    Research Interests: cancer, cellular and molecular mechanisms, diagnostics and therapeutics, gastrointestinal cancer.
  • John F. Seymour
    Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Australia.
    Research Interests: haematology, aggressive lymphoma, acute leukemia, myelodysplasia.
    Contributions:
  • Xiang-Yang Shi
    College of Chemistry, Chemical Engineering and Biotechnology, Donghua Univeristy, Shanghai, China.
    Research Interests: Development of organic/inorganic hybrid nanoplatforms and microfluidic platforms for sensing, imaging, and theranostic applications, in particular for precision cancer imaging and therapy.
  • Alexander Sparreboom
    Division of Pharmaceutics & Pharmaceutical Chemistry College of Pharmacy, The Ohio State University, Columbus, OH, USA.
    Research Interests: platinum-based drugs, tyrosine-kinase inhibitors, P-glycoprotein, cancer chemotherapy, sensitivity analysis, clinical pharmacokinetics.
  • Rakesh K. Srivastava
    Stanley S. Scott Cancer Center, and Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, United States.
    Research Interests: apoptosis, cell signaling and human diseases, molecular mechanisms, stem cells and human diseases, nutrition, diet and cancer.
  • Gary S. Stein
    Department of Biochemistry, University of Vermont Larner College of Medicine, Burlington, VT, USA.
    Research Interests: breast cancer stem cells, genetic and epigenetic of cancer.
  • Ulrike Stein
    Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité – Universitätsmedizin und Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
    Research Interests: key drivers of metastasis, MACC1, S100A4, cancer cell signaling, cancer metastasis, drug discovery.
  • Haruhiko Sugimura
    Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
    Research Interests: cancer biology, genetics, genotyping, cell biology, microscopy, hepatocellular carcinoma, pharmacology, immunohistochemistry, DNA, mutation.
  • Shi-Yong Sun
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.
    Research Interests: regulation of death receptors, TRAIL receptors, small therapeutic molecules, drug-induced apoptosis, Akt/mTOR signaling, cancer therapy, EGFR inhibitors, acquired resistance, lung cancer.
  • Vladimir P. Torchilin
    Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA.
    Research Interests: drug delivery, drug targeting, nanomedicine, liposomes, micelles, experimental cancer therapy.
  • Takanori Ueda
    Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
    Research Interests: leukemia, diffuse large B‐cell lymphoma.
  • Brian A. Van Tine
    Department of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
    Research Interests: soft tissue and bone sarcomas, human-in-mouse sarcoma models, amino acid deprivation therapies, metabolic deficiencies in sarcoma, phase 1 clinical trials.
    Contributions:
  • Robert C.A.M. van Waardenburg
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.
    Research Interests: DNA repair proteins, cellular response to chemotherapy, protein-protein interactions, post-translational modification by ubiquitin and SUMO, sulfotransferases.
    Contributions:
  • Takahiro Yamauchi
    Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
    Research Interests: hematologic malignancies, nucleoside analogs, tyrosine kinase inhibitors, bcl2 inhibitors, antibodies, DNA repair, and pharmacology.
  • Nadia Zaffaroni
    Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
    Research Interests: telomerase, prostatic neoplasms, melanoma, cisplatin, apoptosis, neoplasms.

Former Editorial Board Member

  • Joseph R. Bertino
    Departments of Pharmacology and Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. (Died October 11, 2021 (aged 91))
    Research Interests: cancer biology, lymphomas, antimetabolites.
© 2016-2021 OAE Publishing Inc., except certain content provided by third parties